Pharvaris N.V. (NASDAQ:PHVS) Short Interest Update

Pharvaris N.V. (NASDAQ:PHVS) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 446,000 shares, adropof45.6% from the July 15th total of 819,700 shares. Based on an average daily volume of 103,100 shares, the short-interest ratio is currently 4.3 days. Currently,2.0% of the company’s shares are sold short. Currently,2.0% of the company’s shares are sold short. Based on an average daily volume of 103,100 shares, the short-interest ratio is currently 4.3 days.

Institutional Trading of Pharvaris

Several large investors have recently made changes to their positions in PHVS. Soleus Capital Management L.P. lifted its position in Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after acquiring an additional 216,483 shares in the last quarter. Octagon Capital Advisors LP lifted its position in shares of Pharvaris by 25.4% during the 4th quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after buying an additional 157,530 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in shares of Pharvaris by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock worth $14,859,000 after buying an additional 18,200 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Pharvaris by 36.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock valued at $8,510,000 after acquiring an additional 118,408 shares in the last quarter. Finally, TFG Asset Management GP Ltd increased its position in shares of Pharvaris by 48.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock valued at $3,311,000 after purchasing an additional 61,105 shares during the last quarter.

Pharvaris Stock Performance

Shares of PHVS opened at $22.31 on Monday. The firm’s 50-day simple moving average is $19.71 and its 200 day simple moving average is $17.23. Pharvaris has a 52 week low of $11.51 and a 52 week high of $26.33. The firm has a market cap of $1.17 billion, a P/E ratio of -6.64 and a beta of -2.81.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07). As a group, equities analysts forecast that Pharvaris will post -2.71 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. JMP Securities decreased their price objective on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a report on Wednesday, August 13th. Wedbush restated an “outperform” rating and issued a $27.00 price objective on shares of Pharvaris in a research report on Thursday, June 5th. Cantor Fitzgerald dropped their price objective on Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Finally, Guggenheim assumed coverage on Pharvaris in a research note on Wednesday, June 11th. They issued a “buy” rating and a $32.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pharvaris currently has an average rating of “Buy” and a consensus price target of $35.60.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.